Category Archives: Science: Biology

Cutting edge research is happening on a daily basis in our modern world, Keep up to date with our Press Release services.

UpScapers & Vistafolia Release First & Only, Sound Absorbing Artificial Green Wall System


Partner with the Best
UpScapers vertical greening works exclusively with VistaFolia, London, to provide the highest quality artificial green walls to clients and resellers throughout the United States, Canada & Mexico. With more than 10 years of replica landscape experience, UpScapers provides hands-on certified installation training to VistaFolia Authorized Resellers in the U.S. for a quality installation you can trust.

UpScapers & Vistafolia Release First & Only, Sound Absorbing Artificial Green Wall System

“UpScapers is eager to take this new and innovative Vistafolia Hush system to the noise control market,” said Jackie Wiener, UpScapers Co-Founder. “This is a true innovation and raises the bar in aesthetics for acoustic panels”.

UpScapers and Vistafolia released the first and only artificial green wall system recently, Vistafolia Hush, with near-perfect sound-absorbing capabilities.

The system, created in partnership between UpScapers and Vistafolia, gives clients in the Americas a low-maintenance, sound-absorbing biophilic design solution.

Vistafolia Hush is a ground-breaking design unmatched in the market today, featuring 16 varieties of plants, hand-tied in a patent-pending growing pattern for a seamless, bespoke look. The flawless visual profile makes it perfect for classrooms, performance halls, jury areas, conference rooms, or any space that needs sound control while maintaining and enhancing the beauty of the space and incorporating biophilic design. The construction is lightweight and can be cut or shaped to almost any size for instant greening benefits.

“UpScapers is eager to take this new and innovative Vistafolia Hush system to the noise control market,” said Jackie Wiener, UpScapers Co-Founder. “This is a true innovation and raises the bar in aesthetics for acoustic panels.”

All plants and panels are hand secured and assembled by experts, with trained and certified local installation services available. The versatile design allows installation onto nearly any surface or opening. Optional features include custom finishing with a variety of plant color and texture choices.

“We’re delighted to have worked in conjunction with Vistafolia on a project that will greatly expand our benefits in the design community and to our clients,” Wiener said. “As the original and leaders in the industry, we continue to work together to innovate and expand the capabilities of faux green walls, pushing the boundaries of what is possible. This along with Vistafolia’s push to become the first and only manufacturer moving to a bio-based polymer will represent a huge step forward for the future of artificial plants and will serve to strengthen our position as the definitive resource for replica green walls in the Americas and islands.”

About UpScapers

Established in 2020, UpScapers designs and installs Vistafolia replica green walls and potted foliage (The Flawless Flowerpot ™), as well as live plant green walls throughout the Americas and surrounding Islands. UpScapers supplies, trains and supports a vast network of certified Vistafolia Resellers and is invested in educating the architectural & design community on biophilic design benefits and the faux greening trend.

About Vistafolia

Established in 2014, Vistafolia designs, manufactures, and supplies unique and versatile ultra-realistic lush artificial green wall systems which are sold globally and work in conjunction with UpScapers to service and train its reseller base in the Americas and surrounding islands.

Share article on social media or email:

CE mark awarded to iThera Medical’s MSOT Acuity Echo imaging system – a major milestone for Horizon 2020 Project EUPHORIA


We are very excited about the CE certification of our MSOT Acuity Echo system.

“We are very excited about the CE certification of our MSOT Acuity Echo system. The integration of ultrasound imaging is key for clinical users of optoacoustics” said Christian Wiest, CEO and co-founder of iThera Medical. Dr Philipp Bell, Chief Commercial Officer at iThera and Coordinator of EUPHORIA said “Obtaining the CE mark is a major milestone for the EUPHORIA project. We see huge potential for the MSOT Acuity Echo and the opportunity for non-invasive patient imaging that it presents”.

MSOT (multispectral optoacoustic tomography) is based on the photoacoustic effect (the emission of acoustic signals following light absorption). MSOT has the unique capability to visualize optical contrast at high resolution, in deep tissue in real time. By tuning the wavelength of the excitation laser, it can discriminate tissue chromophores that have a characteristic spectrum in the near-infrared; particularly hemoglobin, lipids, collagen, and water. The combination of optoacoustic imaging with ultrasound allows the clinician to identify relevant anatomical structures based on the ultrasound image and then probe the tissue of interest for functional and molecular biomarkers using MSOT.

The technology behind iThera’s MSOT Acuity Echo was optimized as part of the EU Horizon 2020 EUPHORIA Project. The project aims to test the efficacy of the new system as a clinical tool for non-invasive monitoring of Inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis. A multi-site clinical study in people with IBD is currently underway in four hospitals in Germany and Italy.

Initial research suggests there are a wide range of potential clinical applications for MSOT and the MSOT Acuity Echo. With the receipt of the CE mark, clinical researchers can now readily explore the clinical value of MSOT, even following the imminent introduction of the new Medical Device Regulation.

About the EUPHORIA Project

The EUPHORIA Project is an EU funded Fast Track to Innovation project led by iThera Medical. The Project also involves University Hospital Erlangen (Germany), IMASONIC SAS (France), Rayfos Ltd (UK) and Pintail Ltd (Ireland). The Project is focused on optimizing iThera Medical’s MSOT Acuity Echo, testing its efficacy in a large clinical study, achieving CE marking for the device, validating clinical utility and demonstrating benefits for those with IBD. The consortium is also exploring potential health economic impacts and plans are being developed to bring this novel technology to the market-place and to the clinic. You can find out more about the EUPHORIA Project at https://euphoria2020.eu/.

For further information, please contact:

Nora Ward

Email: nora.b.ward@pintailservices.com

The EUPHORIA Project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 830965. The material presented and views expressed here are the responsibility of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.

Share article on social media or email:

FDAnews Announces — Rethinking the Life Sciences Training Technology Ecosystem Free Webinar Sponsored by Veeva June 15, 2021


WCG FDAnews

WCG FDAnews

Rethinking the Life Sciences Training Technology Ecosystem

A Free FDAnews Webinar Sponsored by Veeva

Tuesday, June 15, 2021, 11:00 a.m.-12:00 p.m. EDT

https://info.fdanews.com/rethinking-life-sciences-training-tech-ecosystem?free_webinar_source=HP

Life sciences leaders are rethinking their approach to training. Rather than viewing training solely as an expense associated with risk avoidance, organizations that have efficient and effective training programs are directly influencing their critical quality metrics and enjoying a competitive advantage.

As a result, the conversation about investing in training technology has also changed. Specifically, companies are seeking ways to streamline training technologies to create unified experiences for administrators and learners alike.

Join us for a webinar on June 15, called “Rethinking the Life Sciences Training Technology Ecosystem.” To fully understand how all pieces of the training technology landscape fit into your organizational picture, we’ll cover topics such as:


  • Key definitions and descriptions of modern training technology categories
  • How to prioritize acquiring new job technologies and eliminating legacy solutions
  • Best practices for effectively connecting systems and processes to ensure faster time to qualification and competency, as well as a deep dive into:
  • Authoring tools
  • Document and Content Management Systems
  • Learning Management Systems
  • Gamification Frameworks
  • Learning Experience Platforms

Whether your company is just getting started, moving away from a paper-based approach, or looking to replace legacy systems, this webinar will help you make the right choices when evaluating training technologies.

Webinar Details:

Rethinking the Life Sciences Training Technology Ecosystem

A Free FDAnews Webinar Sponsored by Veeva

Tuesday, June 15, 2021, 11:00 a.m.-12:00 p.m. EDT

https://info.fdanews.com/rethinking-life-sciences-training-tech-ecosystem?free_webinar_source=HP

Easy Ways to Register:

Online: https://info.fdanews.com/rethinking-life-sciences-training-tech-ecosystem?free_webinar_source=HP

By phone: 888.838.5578 or 703.538.7600

About FDAnews:

FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on FDAnews’ print and electronic newsletters, books and conferences to stay in compliance with international standards and the FDA’s complex and ever-changing regulations

Share article on social media or email:

Endurance Athlete Living with Ankylosing Spondylitis Undertakes 2,855-mile Journey to Benefit Spondylitis Association of America


Helgi Olafson, endurance athlete living with ankylosing spondylitis

This is a journey that has never been attempted before and may never be attempted again.

Helgi Olafson, a health activist, professional yacht chef, and endurance athlete living with ankylosing spondylitis, will undertake an epic journey to benefit the Spondylitis Association of America. On August 13, 2021 Olafson will kick off the Triple Crown of 200s, three original non-repetitive 200-mile trail running courses in the USA. Olafson will attempt to cover the entire 2,855 miles by foot over the course of 61 days.

Olafson will begin his adventure with Bigfoot 200, a 206.5-mile ultramarathon with an elevation change of +42,506 ft and -43,906 ft. that takes place in the Northern Cascade Mountains and the iconic Mt. Saint Helens. Once this race is complete, Olafson and pacers, supported by a team of two and a 4×4 roving aid station, will make their way south via the Pacific Crest Trail (PCT), attempting to break the overall supported speed record for the 453-mile Oregon section along the way. Once through Oregon, Olafson will continue south via the PCT to compete in the 2nd race of the Triple Crown, the Tahoe 200, which circumnavigates Lake Tahoe. This race covers 205.5 miles with an elevation change of +40,200 ft and -40,200 ft. From Tahoe, Olafson will continue east on the American Discovery Trail (ADT) toward Moab, Utah. During this section, Olafson will attempt the 496 mile overall supported speed record on the ADT through Nevada. The Moab 240 is the third and final race of the Triple Crown, with 240.3 miles and an elevation change of +29,467 ft and -29,467 ft.

One in every 100 people in the U.S. has spondyloarthrits, the name given to a group of closely related rheumatic diseases that primarily affect the spine and other joints. Olafson has been living with ankylosing spondylitis, a form of spondyloarthritis, since he was diagnosed at the age of 19. Olafson is asking that donations made in support of his journey be directed to the Spondylitis Association of America. “When I was diagnosed, I didn’t know that there were more than 3 million people in the U.S. living with this disease. It’s important for me to help raise awareness and support the work of SAA,” says Olafson. “This is a journey that has never been attempted before and may never be attempted again,” he adds.

Olafson will adhere to a detailed itinerary and follow an exact predetermined route wherever possible. Using GPS satellite tracking, Olafson and his crew will be tracked in real time as he progresses through the challenge. They will also share photos and messages via social media.

To learn more about Olafson and the fundraiser, visit Helgi’s fundraiser on spondylitis.org.

About the Spondylitis Association of America

Since our founding in 1983, the Spondylitis Association of America has been the leading national nonprofit providing educational resources, connections, and the critical emotional support that people living with spondylitis need. SAA is committed to increasing awareness of spondylitis, providing information and support to patients and their families, and funding research to ultimately uncover a cure for the disease.

Share article on social media or email:

Corteva Agriscience Collaborates with Elemental Enzymes to Provide Farmers with Abiotic Stress Mitigation Technology


News Image

This agreement is another demonstration of Corteva Agriscience’s commitment to provide farmers biological solutions that offer proven, predictable performance in complement with our broad portfolio of conventional crop protection and seed solutions, as well as digital tools.

Corteva Agriscience and Elemental Enzymes, a life sciences company that develops novel biotechnology and enzymes solutions, announced today a multi-year global agreement around a unique abiotic stress mitigation technology.

Through the agreement, Corteva receives an exclusive license to Elemental Enzymes’s Waterflux® technology. The optimized osmoprotectant blend provides plants with small organic molecules that help crops overcome abiotic stressors such as soil salinity, drought, and extreme temperatures, helping keep them productive and healthy.

Corteva will offer this technology through a family of products to be branded under the name Sosdia™ Abiotic Stress Mitigator/Biostimulant. Two different products and formulations will be offered for a broad range of crops, including specialty and row crops, sugar cane, and turf and ornamental, as well as range and pasture. Pending appropriate registrations, Corteva will launch the products globally, excluding Australia and New Zealand territories.

“This agreement is another demonstration of Corteva Agriscience’s commitment to provide farmers biological solutions that offer proven, predictable performance in complement with our broad portfolio of conventional crop protection and seed solutions, as well as digital tools,” said Rajan Gajaria, Executive Vice President, Business Platforms, Corteva Agriscience. “We’re pleased to work with Elemental Enzymes to help farmers access new and innovative solutions that enhance plant resilience and growth under challenging environmental conditions, helping keep crops productive and healthy.”

“We are excited to partner with Corteva Agriscience to deliver a new tool to growers that helps manage water related stresses and increase water use efficiency in both the row crop and specialty crop markets,” said Brian Thompson, Chief Executive Officer of Elemental Enzymes. “Crops around the world are increasingly exposed to water and drought stresses that rob growers of yield. Waterflux® Technology allows growers to both maximize their water usage and protect against adverse conditions for their farms.”

Corteva’s model for developing its best-in-class Biologicals portfolio combines external innovation, R&D collaboration, licensing, and distribution. This agreement shows how Corteva collaborates with leading companies to accelerate commercializing customer-centered innovations. Waterflux® technology from Elemental Enzymes will provide value through Sosdia™ Abiotic Stress Mitigator/Biostimulants to improve consistency under environmental stress and enhancing yield potential and sustainability, in line with the Corteva Agriscience 2030 Sustainability Goals.

Both companies are assessing additional technologies for further potential collaboration. Terms of the agreement were not disclosed.

About Corteva

Corteva, Inc. (NYSE: CTVA) is a publicly traded, global pure-play agriculture company that provides farmers around the world with the most complete portfolio in the industry – including a balanced and diverse mix of seed, crop protection and digital solutions focused on maximizing productivity to enhance yield and profitability. With some of the most recognized brands in agriculture and an industry-leading product and technology pipeline well positioned to drive growth, the company is committed to working with stakeholders throughout the food system as it fulfills its promise to enrich the lives of those who produce and those who consume, ensuring progress for generations to come. Corteva Agriscience became an independent public company on June 1, 2019, and was previously the Agriculture Division of DowDuPont. More information can be found at http://www.corteva.com.

Follow Corteva Agriscience on Facebook, Instagram, LinkedIn, Twitter and YouTube.

About Elemental Enzymes

Elemental Enzymes, a St. Louis based company, is catalyzing the future of agriculture with innovative, cross-disciplinary scientific solutions to solve complex problems impacting growers today. Elemental Enzymes creates patented enzymes, peptides and biochemical solutions that improve nutrient uptake, water management and water use efficiency, plant health and yield, as well as disease protection. For more information, visit http://www.elementalenzymes.com.

Follow Elemental Enzymes on LinkedIn.

# # #

Cautionary Statement About Forward-Looking Statements

This communication contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and may be identified by their use of words like “plans,” “expects,” “will,” “anticipates,” “believes,” “intends,” “projects,” or other words of similar meaning. All statements that address expectations or projections about the future, including statements about Corteva’s growth, product development, and sustainability goals, are forward-looking statements.

Forward-looking statements are based on certain assumptions and expectations of future events which may not be accurate or realized. Forward-looking statements also involve risks and uncertainties, many of which are beyond Corteva’s control. While the list of factors presented below is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on Corteva’s business, results of operations and financial condition. Some of the important factors that could cause Corteva’s actual results to differ materially from those projected in any such forward-looking statements include: (i) failure to obtain or maintain the necessary regulatory approvals for some of Corteva’s products; (ii) failure to successfully develop and commercialize Corteva’s pipeline; (iii) effect of the degree of public understanding and acceptance or perceived public acceptance of Corteva’s biotechnology and other agricultural products; (iv) effect of changes in agricultural and related policies of governments and international organizations; (v) effect of competition and consolidation in Corteva’s industry; (vi) effect of competition from manufacturers of generic products; (vii) costs of complying with evolving regulatory requirements and the effect of actual or alleged violations of environmental laws or permit requirements; (viii) effect of climate change and unpredictable seasonal and weather factors; (ix) risks related to oil and commodity markets; (x) competitor’s establishment of an intermediary platform for distribution of Corteva’s products; (xi) impact of Corteva’s dependence on third parties with respect to certain of its raw materials or licenses and commercialization; (xii) effect of industrial espionage and other disruptions to Corteva’s supply chain, information technology or network systems; (xiii) effect of volatility in Corteva’s input costs; (xiv) failure to realize the anticipated benefits of the internal reorganizations taken by DowDuPont in connection with the spin-off of Corteva and other cost savings initiatives; (xv) failure to raise capital through the capital markets or short-term borrowings on terms acceptable to Corteva; (xvi) failure of Corteva’s customers to pay their debts to Corteva, including customer financing programs; (xvii) increases in pension and other post-employment benefit plan funding obligations; (xviii) risks related to the indemnification obligations of legacy E. I. du Pont de Nemours and Company liabilities in connection with the separation of Corteva; (xix) effect of compliance with laws and requirements and adverse judgments on litigation; (xx) risks related to Corteva’s global operations; (xxi) failure to effectively manage acquisitions, divestitures, alliances and other portfolio actions; (xxii) risks related to COVID-19; (xxiii) risks related to activist stockholders; (xxiv) failure to enforce Corteva’s intellectual property rights or defend against intellectual property claims asserted by others; (xxv) effect of counterfeit products; (xxvi) Corteva’s dependence on intellectual property cross-license agreements; and (xxvii) other risks related to the separation from DowDuPont. Additionally, there may be other risks and uncertainties that Corteva is unable to currently identify or that Corteva does not currently expect to have a material impact on its business. Where, in any forward-looking statement an expectation or belief as to future results or events is expressed, such expectation or belief is based on the current plans and expectations of Corteva’s management and expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the expectation or belief will result or be achieved or accomplished. Corteva disclaims and does not undertake any obligation to update or revise any forward-looking statement, except as required by applicable law. A detailed discussion of some of the significant risks and uncertainties which may cause results and events to differ materially from such forward-looking statements or other estimates is included in the “Risk Factors” section of Corteva’s Annual Report on Form 10-K.

06/01/21

TM ® SM Trademarks and service marks of Corteva Agriscience and its affiliated companies, except Waterflux®, trademark of Elemental Enzymes.

Center for Genomic Interpretation Launches ELEVATEGENETICS BRILLIANT Program™


News Image

“Inaccurate genetic/genomic test results often lead to inappropriate downstream medical care that can harm patients and are wasteful to the healthcare system,” notes Julie Eggington, MS, PhD, CGI’s CEO and co-founder.

The Center for Genomic Interpretation (CGI) recently launched the ELEVATEGENETICS BRILLIANT™ Program. The innovative technical competency assessment is a game changer in evaluating the accuracy of genetic and genomic lab findings. The new program fills existing regulatory and accreditation gaps by assessing how well laboratory DNA sequencing tests can detect and rigorously classify important mutations and therapeutic biomarkers, especially in genetic sequences that are technically challenging. The dynamic CGI solution supports a wide range of stakeholders by helping ensure more accurate genetic/genomic testing and reporting, which improves the fidelity of patient treatment plans and promotes better clinical outcomes.

“Inaccurate genetic/genomic test results often lead to inappropriate downstream medical care that can harm patients and are wasteful to the healthcare system,” notes Julie Eggington, MS, PhD, CGI’s CEO and co-founder. “Seemingly equivalent genetic/genomic testing laboratories that have all the same accreditations and regulatory approvals can vary greatly in their results. While no diagnostic test is perfect in every scenario, efforts must be made to protect patients from diagnostic tests with flaws that can be discovered through independent evaluation. We need solutions that improve the accuracy of genetic/genomic testing by addressing these deficiencies to promote better clinical and financial outcomes.”

The ELEVATEGENETICS BRILLIANT Program uses advanced in silico proficiency testing to assess widely used next generation sequencing (NGS) technologies. The Program can be used to evaluate the competency of hereditary or germline disease tests, as well as solid or liquid tumor profiling tests.

“I am excited to be part of CGI’s ELEVATEGENETICS BRILLIANT program,” adds John Pfeifer, MD, PhD. “Many genetics/genomics tests have not been sufficiently evaluated for their ability to detect important and common types of disease variants. This lack of validation results in diagnostic, prognostic and theragnostic tests with higher than necessary false negative rates. BRILLIANT fills the need for more sophisticated variant detection validation.” Dr. Pfeifer is a member of CGI’s Standards Committee and a thought leader in molecular genetic testing protocols.

CGI is offering several unique ELEVATEGENETICS programs that establish meaningful and actionable pathways to improve genetic/genomic testing, analysis and reporting. For payers, ELEVATEGENETICS metrics offer unique evaluations when selecting and contracting with laboratories. For laboratories, these programs offer a unique third-party review focusing on key aspects of the genetic/genomic testing process which can dramatically improve the accuracy of test findings.

For more information about CGI, see http://www.genomicinterpretation.org.

The Center for Genomic Interpretation – http://www.genomicinterpretation.org

The Center for Genomic Interpretation (CGI) is an independent 501(c)(3) nonprofit organization with the mission to save and improve lives through encouraging careful stewardship of clinical genetics, genomics and precision medicine. Too frequently the precision medicine goals of patients and their providers are unknowingly thwarted by inaccurate or ineffective genetic or genomic testing. We facilitate the realization of value from among the confusing scramble of the new precision medicine era. The CGI team consists of clinical genetics and genomics scientific leaders, healthcare policy veterans, experienced business professionals, and others dedicated to helping stakeholders achieve the vision and promise of precision medicine. CGI offers a range of programs and services targeted to all stakeholders including patients, providers, payers, pharmaceutical developers, policy makers and laboratories.

Share article on social media or email:

Galapagos Giant Tortoise Rediscovery Confirmed


Fernandina Giant Tortoise

“Fern,” the female tortoise found on Fernandina Island in 2019.

To avoid the same tragic fate as Lonesome George – the last Pinta Giant Tortoise who died in 2012 – an urgent expedition to Fernandina Island will be launched by GNPD and Galapagos Conservancy to find a mate and save the species.

Scientists at Yale University have confirmed genetic similarity between a lone female Giant Tortoise recently discovered on Fernandina Island and the Fernandina Giant Tortoise (Chelonoidis phantasticus), last reported 112 years ago and long considered lost forever. The female Giant Tortoise was found during a 2019 joint expedition of the Galapagos National Park Directorate (GNPD) and Galapagos Conservancy. To avoid the same tragic fate as Lonesome George – the last Pinta Giant Tortoise who died in 2012 – an urgent expedition to Fernandina Island will be launched by GNPD and Galapagos Conservancy to find a mate and save the species.

At the time of discovery, the GNPD and Galapagos Conservancy team was confident that the female Giant Tortoise was the lost Fernandina Giant Tortoise. However, to verify their assumption, a blood sample was sent to geneticists at Yale, where a team led by Dr. Gisella Caccone sought to uncover the genetic origin of the female tortoise and determine how closely it matched the only other tortoise ever found on Fernandina Island, a now-deceased large male found in 1906.

Nicknamed “Fern” by her discoverers, genetic analysis has now confirmed that she is related to the Chelonoidis phantasticus tortoise species native to the island. These findings verify what researchers at Galapagos Conservancy and GNPD had long hoped for.

“One of the greatest mysteries in Galapagos has been the Fernandina Island Giant Tortoise. Rediscovering this lost species may have occurred just in the nick of time to save it. We now urgently need to complete the search of the island to find other tortoises,” said Dr. James Gibbs, Vice President of Science and Conservation for the Galapagos Conservancy and tortoise expert at the State University of New York.

“We desperately want to avoid the fate of Lonesome George,” said Danny Rueda Córdova, Director of the Galapagos National Park Directorate. “My team from the Park and Galapagos Conservancy are planning a series of major expeditions to return to Fernandina Island to search for additional tortoises beginning this September.”

Fernandina Island’s landscape is dominated by an active volcano that makes expeditions very challenging. If a male tortoise is located on the volcanic terrain, he will be united with the lone female at the Galapagos National Park’s Giant Tortoise Breeding Center in Santa Cruz. Scientists would then oversee breeding efforts, rear any young safely in captivity, and eventually return them to safe habitats on their native island of Fernandina.

Prior to the 2019 discovery, only one specimen of the Fernandina Giant Tortoise had ever been found — a male collected during the California Academy of Sciences expedition in 1905-06. While populations of Giant Tortoises were decimated throughout the Galapagos archipelago in the 19th century due to exploitation by whalers and buccaneers, the Fernandina Giant Tortoise species was believed to be extinct due to volcanic eruptions in past centuries. The current population of Giant Tortoises throughout the Islands is only 10-15% of its historical numbers, estimated between 200,000-300,000 individuals.

But there is hope. Park rangers have found signs (tracks and scat) of at least two other tortoises on Fernandina Volcano during the searches that resulted in the discovery of the lone female. Galapagos Conservancy has launched an urgent appeal at galapagos.org/savethefernandinatortoise to raise funds to undertake the expedition to find these and perhaps other tortoises to save this species from the brink of extinction.

About Galapagos Conservancy: For more than 35 years, Galapagos Conservancy has helped protect the unique biodiversity and ecosystems of Galapagos by supporting research, conservation, outreach, and building a sustainable society. Galapagos Conservancy is the only US-based organization focused exclusively on protecting the Galapagos archipelago. The Galapagos Conservancy and the Galapagos National Park Directorate work together on the Giant Tortoise Restoration Initiative — a collaborative effort to restore tortoise populations to their historical distribution and numbers across Galapagos.

Images for Media Use: Unrestricted use with credits to “Galapagos Conservancy” and photographer(s) listed in each image. View album.

U.S. Contact:

Marc Ford, Galapagos Conservancy

marc@galapagos.org

703-383-0077

Share article on social media or email:

CE Mark awarded to iThera Medical’s second-generation MSOT Acuity Echo optoacoustic imaging system


With the imminent introduction of the strict MDR regulations adding complexity to the life of clinical researchers, users can now rely on a CE-marked device for their clinical trials

“We are very excited about the CE certification of our MSOT Acuity Echo system. The integration of ultrasound imaging is key for clinical users of optoacoustics. With the imminent introduction of the strict MDR regulations adding complexity to the life of clinical researchers, users can now rely on a CE-marked device for their clinical trials”, said Christian Wiest, CEO and co-founder of iThera Medical.

MSOT (multispectral optoacoustic tomography) is based on the photoacoustic effect which describes the emission of acoustic signals following light absorption. MSOT has the unique capability to visualize optical contrast at high resolution, in deep tissue in real time. By tuning the wavelength of the excitation laser, it can discriminate tissue chromophores that have a characteristic spectrum in the near-infrared; particularly hemoglobin, lipids, collagen, and water.

In addition to the MSOT image, the MSOT Acuity Echo now features a real-time tomographic ultrasound image. The co-registration of these two imaging modes gives the clinician confidence to identify relevant anatomical structures based on the ultrasound image and then probe the tissue of interest for functional and molecular biomarkers using MSOT.

Initial research suggests that MSOT imaging could provide clinical value for a wide range of diagnostic imaging applications. Exploratory clinical trials have already been successfully completed in the fields of inflammation, cancer, fibrosis as well as cardiovascular and metabolic diseases. The first multi-center regulatory trial for a diagnostic application is ongoing for the indication of inflammatory bowel disease (IBD). With the receipt of the CE mark, clinical researchers can now readily explore the clinical value of MSOT, even following the imminent introduction of the new MDR (Medical Device Regulation).

ABOUT iTHERA MEDICAL

iThera Medical develops and markets biomedical imaging systems based on a novel technology called Multispectral Optoacoustic Tomography (MSOT). MSOT utilizes the photoacoustic effect – light energy absorbance resulting in acoustic signal emission – to visualize and quantify optical contrast in deep tissue, at high spatiotemporal resolution. MSOT allows the study of disease processes on a functional and molecular level. Recently, MSOT has been translated for clinical use and promises to become a valuable diagnostic tool for a variety of diseases. Find out more about iThera Medical at http://www.ithera-medical.com.

Share article on social media or email:

Harmony Lab & Safety Supplies Announces 2021 Scholarship Winner


Harmony is pleased to announce the 1st winner of our College Scholarship. Shayla Eslampour will receive $1000 towards their education at UC Berkeley, where they major in Molecular Cell Biology. Shayla’s research into sustainable product design and packaging directly impacts the business of Harmony. Shayla is an inspiration to small companies looking to minimize waste utilizing green chemistry technology in their social responsibility program.

Each year, one college student will be granted a $1,000 scholarship from Harmony Lab & Safety Supplies. The contest is open to all students currently enrolled in higher education, with an emphasis on undergraduate students in California.

The project is designed to award outstanding students and celebrate their positive achievements in their community.

“We wanted to recognize students that make an impact in their community” – Sean Clough.

Shayla Eslampour is the first winner of Harmony’s scholarship. In addition to this annual scholarship, Harmony is committed to giving back in other ways.

Harmony Lab & Safety Supplies provides niche swabs, wipes used in microbiology, forensic analysis, and critical environments. In business since 2006, we work with hospitals, cleanrooms, and industrial manufacturers to get them the disposable apparel, gloves, and safety supplies they need.

Harmony Lab & Safety Supplies

12721 Western Ave. Garden Grove, CA 92841

Share article on social media or email:

Mountain Lion Roaming San Francisco Bernal Heights Neighborhood Brought To Oakland Zoo


News Image

Dr. Alex Herman, Vice President of Veterinary Services

We take pride in doing our part to help rescue and protect animals in the wild, through our partnerships and collaboration with CDFW, Bay Area Puma Project, and the San Francisco Police Department

Oakland Zoo assisted with the rescue of a two-year-old male mountain lion found in San Francisco this morning by California Department of Fish and Wildlife (CADFW) officers. He was transported to Oakland Zoo for a temporary stay while receiving a complete exam, bloodwork, and preventative care vaccines.

Mr. Handsome, unofficially named by Oakland Zoo veterinary staff, was placed in a holding area of the Zoo’s Veterinary Hospital overnight until examinations this morning. He was determined to have a total bill of health- strong, hydrated, and at a healthy weight of 98.5 lbs. He was treated for internal and external parasites (common in wildlife) and given vaccinations during his exam.

‘Long-range travel’ into urban neighborhoods isn’t out of the ordinary for mountain lions of this age. Mountain lions are long-ranging species known to exhibit ‘dispersing behavior’, causing them to travel long distances searching for food, good homes, and mates.

“We take pride in doing our part to help rescue and protect animals in the wild, through our partnerships and collaboration with CDFW, Bay Area Puma Project, and the San Francisco Police Department” says Dr. Herman, Vice President of Veterinary Services at Oakland Zoo.

Mr. Handsome is currently on his way to be released in a rural, unpopulated area of Santa Clara County by CDFW, to continue living freely in the wild.

Mountain lions face numerous threats in California, often struck by cars, killed with depredation permits, and illegal poaching. These factors culminate in the human-wildlife conflict, putting them at odds with humans, encroaching urban areas and developments. Oakland Zoo partners with conservation organizations like the Mountain Lion Foundation and the Bay Area Puma Project to educate the public on the issue and help conserve the species in the wild.

Oakland Zoo helped found BACAT (Bay Area Cougar Action Team) in 2013, an alliance with the Bay Area Puma Project and the Mountain Lion Foundation, to help support the CADFW to save mountain lions caught in the human-wildlife conflict.

Contact:

Erin Harrison

Oakland Zoo

eharrison@oaklandzoo.org

Office: 510-632-9525 ext. 120

Cell: 415-601-1619

Isabella Linares

Oakland Zoo

ilinares@oaklandzoo.org

Office: 510-632-9525 ext. 239

Cell: 650 – 776 -9589

###

ABOUT OAKLAND ZOO AND THE CONSERVATION SOCIETY OF CALIFORNIA:

Oakland Zoo, home to more than 850 native and exotic animals, is managed by the Conservation Society of California (CSC); a non-profit organization leading an informed and inspired community to take action for wildlife locally and globally. With over 25 conservation partners and projects worldwide, the CSC is committed to conservation-based education and saving species and their habitats in the wild. Oakland Zoo is dedicated to the humane treatment of animals and is accredited by the Association of Zoos and Aquariums (AZA), the national organization that sets the highest standards for animal welfare for zoos and aquariums.

Share article on social media or email: